These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36343291)

  • 1. Efficacy, safety and tolerability of bosentan as an adjuvant to sildenafil and sildenafil alone in persistant pulmonary hypertension of newborn (PPHN).
    Vijay Kumar JR; Natraj Setty HS; Jayaranganath M; Manjunath CN
    Interv Med Appl Sci; 2021 Aug; 11(4):216-220. PubMed ID: 36343291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent Pulmonary Hypertension of the Newborn: The Efficacy Comparison of Vasodilators Sildenafil Plus Bosentan Versus Sildenafil Plus Beraprost at a Tertiary Childcare Health Facility.
    Adnan M; Arshad MS; Anwar-Ul-Haq HM; Ahmad M; Afsheen H; Raza H
    Cureus; 2021 Nov; 13(11):e20020. PubMed ID: 34987908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial.
    Kashaki M; Mohazzab A; Radgoudarzi M; Bordbar A; Dabbagh S
    Pediatr Neonatol; 2024 May; ():. PubMed ID: 38797632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital.
    Kamran A; Rafiq N; Khalid A; Amin F; Kumari V; Shaikh AS; Tebha SS; Patel N
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6787-6793. PubMed ID: 33980104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral drugs used to treat persistent pulmonary hypertension of the newborn.
    Zhang W; Wu YE; Yang XY; Shi J; van den Anker J; Song LL; Zhao W
    Expert Rev Clin Pharmacol; 2020 Dec; 13(12):1295-1308. PubMed ID: 33180564
    [No Abstract]   [Full Text] [Related]  

  • 6. Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants.
    More K; Athalye-Jape GK; Rao SC; Patole SK
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010531. PubMed ID: 27535894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison Of The Efficacy Of Sildenafil Alone Versus Sildenafil Plus Bosentan In Newborns With Persistent Pulmonary Hypertension.
    Fatima N; Arshad S; Quddusi AI; Rehman A; Nadeem A; Iqbal I
    J Ayub Med Coll Abbottabad; 2018; 30(3):333-336. PubMed ID: 30465360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bosentan therapy in persistent pulmonary hypertension of the newborn.
    Maneenil G; Thatrimontrichai A; Janjindamai W; Dissaneevate S
    Pediatr Neonatol; 2018 Feb; 59(1):58-64. PubMed ID: 28735030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of treprostinil and oral sildenafil for the treatment of persistent pulmonary hypertension of the newborn: a retrospective cohort study.
    Wei E; Chen XH; Zhou SJ
    Front Pediatr; 2023; 11():1270712. PubMed ID: 38027274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 11. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
    Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ
    Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral sildenafil and inhaled iloprost in the treatment of pulmonary hypertension of the newborn.
    Kahveci H; Yilmaz O; Avsar UZ; Ciftel M; Kilic O; Laloglu F; Ozturk K
    Pediatr Pulmonol; 2014 Dec; 49(12):1205-13. PubMed ID: 24420987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial.
    Pierce CM; Zhang MH; Jonsson B; Iorga D; Cheruvu N; Balagtas CC; Steinhorn RH
    J Pediatr; 2021 Oct; 237():154-161.e3. PubMed ID: 34052232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.
    Mouchaers KT; Schalij I; Versteilen AM; Hadi AM; van Nieuw Amerongen GP; van Hinsbergh VW; Postmus PE; van der Laarse WJ; Vonk-Noordegraaf A
    Am J Physiol Heart Circ Physiol; 2009 Jul; 297(1):H200-7. PubMed ID: 19395550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy.
    Porhownik NR; Al-Sharif H; Bshouty Z
    Can Respir J; 2008; 15(8):427-30. PubMed ID: 19107243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and Future Treatments for Persistent Pulmonary Hypertension in the Newborn.
    Pedersen J; Hedegaard ER; Simonsen U; Krüger M; Infanger M; Grimm D
    Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):392-406. PubMed ID: 29855164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.